Hyperbaric oxygen therapy (HBOT) is FDA-cleared as an adjunctive treatment for chronic diabetic foot ulcers, and it is one of the few HBOT uses that insurance covers. In the sham-controlled HODFU trial, 52% of HBOT-treated ulcers healed completely at one year versus 29% with placebo. The evidence for preventing amputation is weaker and mixed, and HBOT is not FDA-cleared for diabetic neuropathy or blood sugar control. This guide covers what the research actually shows, the standard protocol, and how coverage works.
Diabetes affects more than 37 million Americans, and its complications range from slow-healing wounds to nerve damage and vascular disease. HBOT works by delivering 100% oxygen at elevated pressure, which raises the amount of oxygen dissolved in blood and tissue and can restart healing processes that diabetes has impaired. For diabetic foot wounds specifically, this is a well-established medical treatment, though the size of the benefit is debated. HBOT is one of several HBOT applications for chronic conditions where oxygen delivery is the limiting factor.
Does HBOT heal diabetic foot ulcers?
Yes, for the right patients. HBOT is FDA-cleared as an adjunct for chronic, non-healing diabetic foot ulcers (Wagner grade 3 or higher) that have failed at least 30 days of standard wound care. The best trial evidence shows it improves complete healing, though its effect on amputation is uncertain.
Diabetic foot ulcers are among the most serious complications of diabetes. As many as a third of people with diabetes develop a foot ulcer during their lifetime, and these wounds are the leading cause of non-traumatic lower-limb amputations in the United States.1 Standard wound care resolves many ulcers, but a meaningful share become chronic and resistant to healing. During HBOT, patients breathe 100% oxygen at 2.0 to 2.4 atmospheres absolute (ATA), which sharply increases dissolved oxygen in blood and tissue. The Undersea and Hyperbaric Medical Society (UHMS) lists diabetic lower-extremity wounds among its approved indications.6
Complete ulcer healing at 1 year with HBOT versus placebo in the sham-controlled HODFU trial (25/48 vs 12/42, P=0.03)
Löndahl et al., Diabetes Care, 2010
What does the research actually say?
The strongest single trial is HODFU (Löndahl et al., 2010), a double-blind study of 94 patients that compared HBOT against hyperbaric air (a genuine placebo). Complete healing at one year reached 52% with HBOT versus 29% with placebo (P=0.03).2 A 2025 systematic review likewise reported faster ulcer size and depth reduction with HBOT in most of the trials it examined.3
The picture on amputation is where honesty matters. The 2015 Cochrane review found that HBOT improved ulcer healing in the short term (around six weeks) but not in the long term, and it found no statistically significant reduction in major amputation (pooled relative risk 0.36, 95% confidence interval 0.11 to 1.18, across five trials).4 The Cochrane authors also flagged design flaws that lowered their confidence. The largest trial in ischemic ulcers, DAMO2CLES (Santema et al., 2018), concluded that HBOT did not confer a benefit in patients with ischemic diabetic foot ulcers, in part because many of the sickest patients could not complete a full course.5
Cochrane 2015 pooled effect of HBOT on major amputation (RR 0.36, 95% CI 0.11 to 1.18): a possible benefit that did not reach statistical significance
Kranke et al., Cochrane Database, 2015
The honest summary: HBOT improves complete healing of chronic diabetic foot ulcers, which is why it is FDA-cleared and covered as an adjunct, but it should not be sold as a proven way to prevent amputation. For a deeper look at the wound-healing data, see our guide on the hyperbaric chamber for wound healing.
How does HBOT work at the cellular level?
Diabetes impairs wound healing through poor blood flow, reduced oxygen delivery, a weakened immune response, and lower growth-factor production. HBOT targets several of these directly:
- Oxygen delivery: hyperbaric conditions can raise tissue oxygen levels well above normal, reaching areas with compromised blood supply.
- Angiogenesis: repeated sessions stimulate new blood vessel growth in oxygen-depleted tissue, restoring circulation to the wound bed.
- Collagen synthesis: oxygen is required for collagen production, the structural protein needed for wound closure.
- Infection control: elevated oxygen enhances white blood cell function and is directly toxic to certain anaerobic bacteria found in diabetic wounds.
Does HBOT help diabetic neuropathy?
Possibly, but the evidence is early and lower quality. Diabetic neuropathy affects up to 50% of people with diabetes, causing numbness, tingling, burning pain, and loss of sensation, most often in the feet and legs. It is driven by nerve damage from high blood sugar, poor microcirculation, and oxidative stress. HBOT is not FDA-cleared for neuropathy.
A 2024 systematic review and meta-analysis (Weng et al.) pooled 14 randomized trials covering 675 HBOT patients and 648 controls, and found that HBOT improved nerve conduction velocities and overall treatment response compared with standard therapy.7 The catch is that many of the included trials were small and of modest methodological quality, so the finding is promising rather than definitive. Larger, rigorous trials are needed before neuropathy becomes a standard indication.
The proposed mechanisms are improved nerve oxygenation (peripheral nerves in diabetes are often oxygen-starved from microvascular disease) and microcirculation restoration through angiogenesis. If neuropathy is your primary concern, our guide on the hyperbaric chamber for neuropathy covers the current evidence in full.
Can HBOT improve blood sugar or insulin sensitivity?
There is no good evidence that it can, and no guideline recommends it for this. A small body of animal studies and early human trials has reported short-lived improvements in fasting glucose or insulin sensitivity after HBOT, with proposed mechanisms involving better mitochondrial function and reduced inflammation. These findings are inconsistent, the effects appear modest, and they may not persist after treatment ends. Anyone considering HBOT for blood sugar management should treat it as an unproven research question, not an established use. For the wider picture across indications, see our HBOT research overview.
Which diabetes indications have the evidence?
HBOT for Diabetes: Evidence by Indication
| Indication | Evidence Level | Key Finding | FDA Status |
|---|---|---|---|
| Foot ulcer healing | Moderate | Löndahl 2010: 52% vs 29% healed at 1 year | Cleared (adjunctive) |
| Amputation prevention | Limited / mixed | Cochrane 2015: no significant difference; DAMO2CLES negative for ischemic ulcers | Part of wound indication |
| Diabetic neuropathy | Emerging | Weng 2024 meta-analysis: better nerve conduction, low-quality trials | Not cleared |
| Glycemic control | Limited | Small, inconsistent studies; effects modest and short-lived | Not cleared |
What is the HBOT protocol for diabetes?
HBOT for diabetic wounds follows well-established clinical guidelines. Neuropathy protocols are not standardized.
Diabetic foot ulcers (standard protocol)
- Pressure: 2.0 to 2.4 ATA (most commonly 2.0 ATA)
- Session length: 90 minutes of oxygen breathing time per session
- Frequency: once daily, five days per week
- Total sessions: 30 to 40 sessions (6 to 8 weeks), with reassessment after 20 sessions
- Setting: hospital-based or outpatient wound center with a medical-grade monoplace or multiplace chamber
Most protocols reassess at 20 sessions. If the wound shows measurable improvement (reduced size or depth), treatment continues. If not, the care team reconsiders the approach. For how a session works and how to prepare, see our full HBOT sessions guide.
Neuropathy (investigational protocol)
There is no standardized protocol for diabetic neuropathy. Research studies have typically used 20 to 30 sessions at 2.0 to 2.4 ATA on a daily schedule similar to wound care.
How much does HBOT cost and does insurance cover it?
Diabetic wound healing is one of the few hyperbaric uses where insurance usually helps. Because it is an FDA-cleared indication, most plans cover HBOT when specific criteria are met:
- The wound is a Wagner grade 3 or higher diabetic foot ulcer (or meets equivalent severity criteria).
- The wound has failed at least 30 days of standard wound care.
- The patient is receiving concurrent comprehensive wound management.
- Treatment is provided in an accredited facility.
Medicare covers HBOT for diabetic wounds under these conditions, and most commercial insurers follow similar rules, typically up to 40 sessions with prior authorization. For neuropathy and metabolic uses, HBOT insurance coverage is unlikely because these are not FDA-cleared, so patients usually pay out of pocket. For the range of self-pay pricing, see our guide to hyperbaric chamber cost.
Who should not use a hyperbaric chamber?
HBOT is generally safe when administered by trained professionals, but it is not appropriate for everyone. Discuss your full medical history with your provider first.
Absolute contraindications
HBOT should not be used if you have:
- Untreated pneumothorax (collapsed lung): pressure changes can worsen this and become life-threatening.
- Certain chemotherapy drugs: bleomycin, cisplatin, doxorubicin, and disulfiram may interact dangerously with high-oxygen environments.
Relative contraindications
Your provider may take extra precautions or postpone treatment if you have:
- Upper respiratory infection or sinus congestion: difficulty equalizing pressure can cause ear or sinus barotrauma.
- Seizure disorder: high-pressure oxygen can lower the seizure threshold in susceptible people.
- Chronic obstructive pulmonary disease (COPD): altered breathing drive may require modified protocols.
- High fever: increases the risk of oxygen toxicity.
- History of ear surgery or chronic ear problems: pressure equalization may be difficult or risky.
- Claustrophobia: may require a multiplace chamber or extra support.
- Pregnancy: safety data for routine use during pregnancy is insufficient.
Even without these conditions, consult your physician before starting HBOT, especially if you take insulin (blood sugar can drop during treatment), have an implanted device, or take any medications. For a full overview, see our guide on HBOT side effects and risks.
Can HBOT cure diabetes?
No. HBOT does not cure diabetes or replace standard diabetes management. It is an adjunctive therapy for specific complications, primarily chronic foot wounds and, on an investigational basis, neuropathy. Blood sugar control through medication, diet, and exercise remains essential. There is no reliable evidence that HBOT lowers HbA1c or reverses insulin resistance in a lasting way.
How soon should I start HBOT for a diabetic wound?
Guidelines recommend HBOT after a diabetic wound has failed to improve with at least 30 days of standard wound care.6 Starting sooner is generally not covered and may be unnecessary, since many wounds respond to conventional treatment. If your wound is deteriorating quickly or amputation is being discussed, ask your doctor about an earlier referral to a wound center.
Is HBOT safe for people with diabetes?
HBOT is considered safe for most people with diabetes. The main risk is hypoglycemia: the increased oxygen and metabolic activity during a session can lower blood sugar. Patients on insulin or sulfonylureas should check their glucose before each session and bring a snack. Most HBOT facilities monitor blood sugar as part of their standard protocol for diabetic patients.
Will my insurance cover HBOT for diabetic neuropathy?
Most likely not. Coverage is tied to FDA-cleared indications, and diabetic neuropathy is not one of them. Diabetic foot ulcers are covered, so if you have both a chronic wound and neuropathy, you may receive benefits during wound-focused treatment. Check with your insurer about prior authorization and appeal strategies before you start.
Sources
- Oliver TI, Mutluoglu M. “Diabetic Foot Ulcer.” StatPearls. NCBI Bookshelf. NBK537328
- Löndahl M, Katzman P, Nilsson A, Hammarlund C. “Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes.” Diabetes Care. 2010;33(5):998-1003. PubMed
- Clinical Outcomes of Hyperbaric Oxygen Therapy for Diabetic Foot Ulcers: A Systematic Review. 2025. PMC11890413
- Kranke P, Bennett MH, Martyn-St James M, Schnabel A, Debus SE, Weibel S. “Hyperbaric oxygen therapy for chronic wounds.” Cochrane Database of Systematic Reviews. 2015;(6):CD004123. PubMed
- Santema KTB, Stoekenbroek RM, Koelemay MJW, et al. “Hyperbaric Oxygen Therapy in the Treatment of Ischemic Lower-Extremity Ulcers in Patients With Diabetes: Results of the DAMO2CLES Multicenter Randomized Clinical Trial.” Diabetes Care. 2018;41(1):112-119. PubMed
- Undersea and Hyperbaric Medical Society. “Indications for Hyperbaric Oxygen Therapy.” uhms.org
- Weng J, Yang H, Xu Z, et al. “Efficacy and safety of hyperbaric oxygen therapy for diabetes peripheral neuropathy: A systematic review and meta-analysis.” Medicine. 2024;103(36):e39699. doi:10.1097/MD.0000000000039699
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
